US biotech AI Therapeutics has begun a phase 2 trial of its LAM-002A, an antiviral drug that has shown promise against the SARS-CoV-2 coronavirus in the lab.
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl